Key Takeaways from Anavex’s Update
• The CHMP issued a “negative trend vote” on blarcamesine’s MAA after Anavex’s oral explanation, with a formal opinion expected in December 2025.  This isn’t a final rejection yet—Anavex plans to request a re-examination, which involves a fresh review by a different CHMP panel, and intends to bolster its submission with additional biomarker data based on CHMP feedback. 
• Despite completing a Phase 2b/3 trial (ANAVEX®2-73-AD-003) showing statistically significant cognitive and functional benefits (e.g., 38.5% slowdown in progression at 50 mg dose vs. placebo), the EMA appears unconvinced by the current dataset, particularly on biomarkers supporting disease modification. 
Prior critiques have flagged issues like inconsistent reporting, reliance on post-hoc analyses (e.g., tipping point methods), and insufficient separation from placebo on key endpoints.  
• Broader context: EMA has recently approved anti-amyloid antibodies (e.g., lecanemab, donanemab) for AD, setting a high bar for efficacy signals, safety, and mechanistic evidence like amyloid/tau reduction or neuroprotection via biomarkers. Blarcamesine’s sigma-1 receptor mechanism (aiming for cellular homeostasis) may not yet align strongly enough without more robust supportive data.
This highlights EMA’s growing stringency for neurodegenerative approvals: Clinical outcomes alone (even from large Phase 3 trials) aren’t enough; integrated biomarker evidence (e.g., CSF/plasma markers of neurodegeneration, imaging, or pharmacodynamic changes) is increasingly pivotal to demonstrate disease-modifying potential and address unmet needs.
- HER-096 Program Overview and Current Status
• HER-096 is Herantis’s lead asset, a subcutaneously administered CDNF (cerebral dopamine neurotrophic factor) mimetic designed to protect and restore degenerating neurons in PD, potentially slowing disease progression without the dopaminergic side effects of current symptomatic treatments.
• The Phase 1b trial (completed dosing in August 2025) enrolled PD patients for repeated twice-weekly doses (200 mg and 300 mg) over four weeks, plus follow-up.  Topline results (announced October 7, 2025) were positive:
• Safety/Tolerability: Generally well-tolerated; mild, transient injection-site reactions were the main adverse events. No serious drug-related issues in active arms (one placebo-related SAE). 
• Pharmacokinetics (PK): Confirmed strong blood-brain barrier penetration and sufficient CSF exposure, consistent with healthy volunteer data—key for a CNS-targeted therapy. 
• Preliminary Efficacy: Motor symptoms (via MDS-UPDRS) remained stable in both active and placebo groups, but the trial wasn’t powered for this (short duration, small n=~30).
• Critically, full exploratory biomarker analysis (targeted/untargeted, e.g., neuroinflammation, dopamine neuron health markers) is still pending and expected by end-2025.   Herantis plans to advance to a Phase 2 efficacy trial in early-stage PD patients in 2026, with 300 mg twice-weekly dosing as the go-forward regimen. 
4. Direct Implications for HER-096
• Heightened Emphasis on Biomarkers: Anavex’s pivot to submit more biomarker data in re-examination mirrors the exact gap Herantis is addressing right now. EMA (and regulators like FDA) increasingly demand biomarker-backed evidence for disease modification in PD/AD—e.g., alpha-synuclein reduction, dopaminergic neuron preservation, or neuroprotection signals via PET/MRI/CSF assays.
- If Herantis’s end-2025 biomarkers show clear pharmacodynamic effects (e.g., reduced neuroinflammation or stabilized dopamine markers), it could de-risk Phase 2 design and future MAA filings, positioning HER-096 as a differentiated option in a field with few disease-modifiers (current PD drugs like levodopa are symptomatic only)
. Weak or inconclusive data, however, could echo Anavex’s hurdles, forcing iterative submissions or trial redesigns later.
• Regulatory Caution for Early-Stage Programs: Anavex reached MAA filing post-Phase 3 but still hit a wall, underscoring that EMA doesn’t grant leniency even for advanced assets without ironclad integrated evidence. For Herantis (pre-Phase 2), this reinforces the need for early EMA engagement (e.g., scientific advice meetings) to align on endpoints. PD’s regulatory path is evolving too—FDA/EMA have accelerated approvals based on biomarkers (e.g., for spinal muscular atrophy analogs), but recent AD precedents show they’re quick to reject if data feels “shaky.” 
Herantis’s orphan drug potential (PD isn’t formally orphan but could qualify subsets) might offer some flexibility, but not immunity.
• No Direct Competition, But Shared Market Dynamics: Blarcamesine (oral, sigma-1 targeted) and HER-096 (subcutaneous, neurotrophic factor) aren’t head-to-head, but both vie for investor/regulator attention in the ~$50B+ neurodegenerative space. Anavex’s ~30% stock drop post-update (worst in 2 years) reflects market sensitivity to EMA signals.  For Herantis (microcap, Helsinki-listed), positive biomarkers could attract partnerships/funding amid this scrutiny, especially with Phase 2 looming. Conversely, any perceived “Anavex effect” might temper enthusiasm for CNS biotechs until Herantis delivers.
• Timeline Risks and Opportunities: With biomarkers due by December 2025 (aligning with Anavex’s re-exam window)
- Herantis has a narrow but pivotal moment. Success here could enable smooth Phase 2 start in H1 2026; delays or underwhelming results might push timelines, mirroring Anavex’s extended path (they’re now eyeing FDA meetings too).  On the upside, Anavex’s dialogue (e.g., with patient communities) shows EMA values stakeholder input—Herantis could leverage PD advocacy groups similarly.
In summary, Anavex’s stall doesn’t doom HER-096 but spotlights biomarkers as the “make-or-break” for EMA success in this space. Herantis’s topline momentum is encouraging, but the full dataset readout will be make-or-break for momentum into Phase 2. If you’re holding or tracking HTI (Herantis ticker), watch the Q4 2025 update closely—it could catalyze upside if biomarkers shine, especially against a backdrop of regulatory realism from cases like this.
- For deeper dives, Herantis’s half-year report notes ongoing grant funding for Phase 2 prep. 
